Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease

Lon S. Schneider, Martin Farlow

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

In light of evidence that estrogen replacement might affect cholinergic function, we examined possible effects of estrogen replacement therapy (ERT) on clinical response to the cholinesterase inhibitor tacrine in women with Alzheimer's disease (AD). In a previously reported 30-week, randomized, double-blind, placebo-controlled, multicenter clinical trial, 14.5% of 318 women with evaluable data had been receiving ERT before randomization. They were randomly assigned to receive placebo or tacrine. Women receiving ERT who were randomized to tacrine improved more than women not receiving ERT who were randomized either to tacrine or to placebo as assessed by cognitive (p < 0.01) and clinical global (p = 0.02) tests. These results provide evidence that prior and continuing ERT may enhance response to tacrine in women with AD. Furthermore, among women on ERT receiving tacrine, there tended to be greater improvement relative to placebo among those without an APOE-ε4 allele. Randomized trials are needed.

Original languageEnglish
Pages (from-to)317-322
Number of pages6
JournalAnnals of the New York Academy of Sciences
Volume826
DOIs
StatePublished - 1997

Fingerprint

Tacrine
Estrogen Replacement Therapy
Alzheimer Disease
Estrogens
Placebos
Cholinesterase Inhibitors
Controlled Clinical Trials
Random Allocation
Estrogen
Therapy
Replacement
Alzheimer's Disease
Cholinergic Agents
Multicenter Studies
Alleles
Placebo

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease. / Schneider, Lon S.; Farlow, Martin.

In: Annals of the New York Academy of Sciences, Vol. 826, 1997, p. 317-322.

Research output: Contribution to journalArticle

@article{84ba2fb757f349aca456028d36ddc6ac,
title = "Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease",
abstract = "In light of evidence that estrogen replacement might affect cholinergic function, we examined possible effects of estrogen replacement therapy (ERT) on clinical response to the cholinesterase inhibitor tacrine in women with Alzheimer's disease (AD). In a previously reported 30-week, randomized, double-blind, placebo-controlled, multicenter clinical trial, 14.5{\%} of 318 women with evaluable data had been receiving ERT before randomization. They were randomly assigned to receive placebo or tacrine. Women receiving ERT who were randomized to tacrine improved more than women not receiving ERT who were randomized either to tacrine or to placebo as assessed by cognitive (p < 0.01) and clinical global (p = 0.02) tests. These results provide evidence that prior and continuing ERT may enhance response to tacrine in women with AD. Furthermore, among women on ERT receiving tacrine, there tended to be greater improvement relative to placebo among those without an APOE-ε4 allele. Randomized trials are needed.",
author = "Schneider, {Lon S.} and Martin Farlow",
year = "1997",
doi = "10.1111/j.1749-6632.1997.tb48482.x",
language = "English",
volume = "826",
pages = "317--322",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease

AU - Schneider, Lon S.

AU - Farlow, Martin

PY - 1997

Y1 - 1997

N2 - In light of evidence that estrogen replacement might affect cholinergic function, we examined possible effects of estrogen replacement therapy (ERT) on clinical response to the cholinesterase inhibitor tacrine in women with Alzheimer's disease (AD). In a previously reported 30-week, randomized, double-blind, placebo-controlled, multicenter clinical trial, 14.5% of 318 women with evaluable data had been receiving ERT before randomization. They were randomly assigned to receive placebo or tacrine. Women receiving ERT who were randomized to tacrine improved more than women not receiving ERT who were randomized either to tacrine or to placebo as assessed by cognitive (p < 0.01) and clinical global (p = 0.02) tests. These results provide evidence that prior and continuing ERT may enhance response to tacrine in women with AD. Furthermore, among women on ERT receiving tacrine, there tended to be greater improvement relative to placebo among those without an APOE-ε4 allele. Randomized trials are needed.

AB - In light of evidence that estrogen replacement might affect cholinergic function, we examined possible effects of estrogen replacement therapy (ERT) on clinical response to the cholinesterase inhibitor tacrine in women with Alzheimer's disease (AD). In a previously reported 30-week, randomized, double-blind, placebo-controlled, multicenter clinical trial, 14.5% of 318 women with evaluable data had been receiving ERT before randomization. They were randomly assigned to receive placebo or tacrine. Women receiving ERT who were randomized to tacrine improved more than women not receiving ERT who were randomized either to tacrine or to placebo as assessed by cognitive (p < 0.01) and clinical global (p = 0.02) tests. These results provide evidence that prior and continuing ERT may enhance response to tacrine in women with AD. Furthermore, among women on ERT receiving tacrine, there tended to be greater improvement relative to placebo among those without an APOE-ε4 allele. Randomized trials are needed.

UR - http://www.scopus.com/inward/record.url?scp=0030723050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030723050&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.1997.tb48482.x

DO - 10.1111/j.1749-6632.1997.tb48482.x

M3 - Article

C2 - 9329702

AN - SCOPUS:0030723050

VL - 826

SP - 317

EP - 322

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -